Hospitalist Doctors in Grosse Pointe, MI Accepting Medicare

2 Hospitalist doctors found. Showing 1 - 2

Swathi R Pasham, M.D Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 22101 Moross Rd, St John Hospital, Grosse Pointe, MI 48236 Phone: 734-464-0887    Fax: 734-402-0254

Manaf Madoun, M.D. Hospitalist Medicare: Accepting Medicare Assignments Practice Location: 468 Cadieux Rd, Grosse Pointe, MI 48230 Phone: 586-552-0269    Fax: 586-279-0833

News Archive

ImmunoGen signs new license agreement with Novartis

ImmunoGen, Inc., a biotechnology company that develops novel anticancer therapeutics using its antibody-drug conjugate technology, today announced that Novartis has licensed the exclusive right to use the Company's ADC technology to develop anticancer therapeutics to an undisclosed target.

Veracyte to present data demonstrating potential of Envisia Genomic Classifier to improve ILD diagnosis

Veracyte, Inc. announced the presentation of data demonstrating that the Envisia Genomic Classifier can help physicians more confidently diagnose interstitial lung disease (ILD), including idiopathic pulmonary fibrosis (IPF), without the need for surgery.

CT scans may be delivering as much radiation as a low-dose atomic bomb

Those full-body CT scans advertised at some health care centers may be delivering as much radiation as a low-dose atomic bomb, according to a new study. And that means people who get them could be raising their cancer risk, researchers from Columbia University report in the journal Radiology (Vol. 232, No. 3:735-738).

Exercise can lower a woman's overall risk of cancer

Exercise is good for more than just your waistline. A recent study presented at the American Association for Cancer Research's Seventh Annual International Conference on Frontiers in Cancer Prevention Research suggests that regular physical activity can lower a woman's overall risk of cancer - but only if she gets a good night's sleep. Otherwise, lack of sleep can undermine exercise's cancer prevention benefits.

Vital Access launches SAVE-2 post-market clinical follow-up study

Vital Access Corporation today announced the launch of the SAVE-2 post-market clinical follow-up study. The SAVE-2 study follows the U.S. SAVE study, an IDE pivotal trial that clearly demonstrated the benefits of the VWING™ Vascular Needle Guide in restoring vascular access to hemodialysis patients with uncannulatable and deep arteriovenous fistulae.

Read more Medical News

› Verified 5 days ago